Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for Tough-to-Treat colon cancer: trial tests promising drug duos

NCT ID NCT07286695

Summary

This study compares two different drug combinations for people with advanced colorectal cancer that has spread and no longer responds to standard chemotherapy. Researchers want to see whether adding fruquintinib or bevacizumab to the chemotherapy drug trifluridine/tipiracil works better to control the cancer and is safer. The trial will enroll about 292 adults whose cancer progressed after at least two prior treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100000, China

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.